Related Experiment Video
Updated: Jun 20, 2026
Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
Published on: January 6, 2015
Phenotypic Drug Screening for Novel Antifibrotic Therapeutics in Lung Health
Xin Wei1, Arun Kumar Verma1, Kevin Merchant1
1Institute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Abstract:
Lung diseases are among the leading causes of death worldwide. Still, noncommunicable pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), are lacking curative pharmacotherapies. Either degradation or excessive production of altered pulmonary extracellular matrix (ECM) is a common key feature of those devastating diseases, respectively. Recapitulating those pathological changes in miniaturized cell culture models is key for phenotypic drug discovery approaches targeting the ECM for novel pharmacotherapies in pulmonary disease. We describe here a phenotypic immunofluorescence-based high-content/high-throughput assay in 384-well plate format to measure ECM deposition activity by primary human lung fibroblasts (phLFs) in a pulmonary fibrosis disease context.
Insights
Developing new lung disease treatments is crucial. This study presents a high-throughput assay to measure extracellular matrix deposition in lung fibroblasts, aiding drug discovery for pulmonary fibrosis and other lung diseases.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Drug Discovery
Background:
- Lung diseases, including COPD and ILD, are major global health issues lacking effective cures.
- Altered pulmonary extracellular matrix (ECM) is a hallmark of these conditions, driving disease progression.
- Developing novel pharmacotherapies targeting ECM is essential for treating pulmonary diseases.
Purpose of the Study:
- To establish a high-content, high-throughput assay for measuring ECM deposition.
- To facilitate phenotypic drug discovery for pulmonary diseases.
- To investigate ECM dynamics in a pulmonary fibrosis model.
Main Methods:
- Development of a phenotypic immunofluorescence-based assay.
- Utilizing a 384-well plate format for scalability.
- Employing primary human lung fibroblasts (phLFs) to model disease.
Main Results:
- Successfully established a robust assay to quantify ECM deposition.
- Demonstrated the assay's utility in a pulmonary fibrosis context.
- Enabled high-throughput screening for potential drug candidates.
Conclusions:
- The developed assay is a valuable tool for advancing drug discovery in pulmonary fibrosis.
- This approach can accelerate the identification of novel pharmacotherapies for lung diseases.
- Phenotypic screening targeting ECM is a promising strategy for treating debilitating pulmonary conditions.
More Related Videos
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
03:38Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
